Meropenem Model-Informed Precision Dosing in the Treatment of Critically Ill Patients: Can We Use It?
The number of pharmacokinetic (PK) models of meropenem is increasing. However, the daily role of these PK models in the clinic remains unclear, especially for critically ill patients. Therefore, we evaluated the published meropenem models on real-world ICU data to assess their suitability for use in...
Main Authors: | Letao Li, Sebastiaan D. T. Sassen, Tim M. J. Ewoldt, Alan Abdulla, Nicole G. M. Hunfeld, Anouk E. Muller, Brenda C. M. de Winter, Henrik Endeman, Birgit C. P. Koch |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/12/2/383 |
Similar Items
-
Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?
by: Letao Li, et al.
Published: (2022-02-01) -
Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial
by: Philipp Simon, et al.
Published: (2020-12-01) -
Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
by: Ute Chiriac, et al.
Published: (2023-06-01) -
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
by: Ahmed A. Abulfathi, et al.
Published: (2021-06-01) -
Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)